Colorectal Cancer Screening in Average Risk Populations: Evidence Summary.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27597935)

Published in Can J Gastroenterol Hepatol on August 14, 2016

Authors

J M Tinmouth1, Emily T Vella2, Nancy N Baxter3, Catherine Dubé4, M Gould5, Amanda Hey6, Nofisat Ismaila7, Bronwen R McCurdy8, Lawrence Paszat9

Author Affiliations

1: Institute for Clinical Evaluative Sciences, Toronto, ON, Canada M4N 3M5; Sunnybrook Health Sciences Centre, Toronto, ON, Canada M4N 3M5; Cancer Care Ontario, Toronto, ON, Canada M5G 2L7; Department of Medicine, University of Toronto, Toronto, ON, Canada M5S 1A8; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada M5T 3M6.
2: Program in Evidence-Based Care, Cancer Care Ontario, Hamilton, ON, Canada.
3: Prevention and Cancer Control, Cancer Care Ontario, Toronto, ON, Canada; Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; Department of Surgery, St. Michael's Hospital, Toronto, ON, Canada; Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada.
4: Prevention and Cancer Control, Cancer Care Ontario, Toronto, ON, Canada; Department of Medicine, Division of Gastroenterology, University of Ottawa, The Ottawa Hospital, Ottawa, ON, Canada.
5: Toronto Digestive Disease Associates Inc, Toronto, ON, Canada L4L 4Y7.
6: Northeast Cancer Centre Health Sciences North/Horizon Santé-Nord, Sudbury Outpatient Centre, Sudbury, ON, Canada.
7: American Society of Clinical Oncology, Alexandria, VA, USA.
8: Prevention and Cancer Control, Cancer Care Ontario, Toronto, ON, Canada.
9: Institute for Clinical Evaluative Sciences and the University of Toronto, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5.

Articles cited by this

Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med (1993) 27.80

Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet (1996) 18.89

Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2008) 16.82

The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol (2003) 16.17

Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology (2008) 15.86

Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet (2010) 15.50

HPV screening for cervical cancer in rural India. N Engl J Med (2009) 14.13

Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol (2007) 13.46

Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med (2000) 13.21

The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med (2000) 13.19

American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol (2009) 12.16

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol (2010) 11.77

Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48

Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med (2014) 11.07

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol (2009) 9.24

Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med (2006) 8.18

Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst (1999) 8.08

Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med (2013) 7.72

CT colonography versus colonoscopy for the detection of advanced neoplasia. N Engl J Med (2007) 7.63

Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med (2012) 7.18

Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med (2000) 6.90

Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med (2004) 6.42

Colonoscopic screening of average-risk women for colorectal neoplasia. N Engl J Med (2005) 5.88

Long-term mortality after screening for colorectal cancer. N Engl J Med (2013) 5.81

Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol (2011) 5.72

Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ (2009) 5.69

Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev (2007) 5.63

Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet (2002) 5.04

Recommendations on screening for breast cancer in average-risk women aged 40-74 years. CMAJ (2011) 4.68

Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology (2008) 4.68

Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut (2010) 4.59

Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA (2014) 4.41

Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA (2016) 4.06

Effect of screening colonoscopy on colorectal cancer incidence and mortality. Clin Gastroenterol Hepatol (2009) 3.96

Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. Gastroenterology (2007) 3.78

Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial--SCORE. J Natl Cancer Inst (2011) 3.75

Meta-analysis: adherence to colorectal cancer screening and the detection rate for advanced neoplasia, according to the type of screening test. Aliment Pharmacol Ther (2012) 3.42

Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy. Gastroenterology (2013) 3.25

A comparison of colorectal neoplasia screening tests: a multicentre community-based study of the impact of consumer choice. Med J Aust (2006) 3.20

Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy"--SCORE. J Natl Cancer Inst (2002) 3.00

Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I. Scand J Gastroenterol (1999) 2.89

Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg (2008) 2.75

Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med (2008) 2.74

The risks of screening: data from the Nottingham randomised controlled trial of faecal occult blood screening for colorectal cancer. Gut (1999) 2.53

Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates. J Natl Cancer Inst (2005) 2.51

Participation in colorectal cancer screening with FOBT and colonoscopy: an Italian, multicentre, randomized population study. Dig Liver Dis (2009) 2.40

The prevalence rate and anatomic location of colorectal adenoma and cancer detected by colonoscopy in average-risk individuals aged 40-80 years. Am J Gastroenterol (2006) 2.34

Systematic review and meta-analysis of the evidence for flexible sigmoidoscopy as a screening method for the prevention of colorectal cancer. Br J Surg (2012) 2.25

Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut (2013) 2.17

Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med (2013) 2.15

Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds. Scand J Gastroenterol (2004) 2.14

Possible advantages and drawbacks of adding flexible sigmoidoscopy to hemoccult-II in screening for colorectal cancer. A randomized study. Scand J Gastroenterol (1999) 2.13

Screening colonoscopy for colorectal cancer in asymptomatic people: a meta-analysis. Dig Dis Sci (2008) 2.03

A prospective study of the prevalence of colonic neoplasms in asymptomatic patients with an age-related risk. Am J Gastroenterol (1990) 2.01

Interval cancers after negative colonoscopy: population-based case-control study. Gut (2011) 1.97

Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ (2014) 1.95

The Norwegian Colorectal Cancer Prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50-64 years. Scand J Gastroenterol (2003) 1.87

Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: a randomized, controlled trial. Prev Med (2010) 1.79

Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut (2011) 1.67

Population based randomized study of uptake and yield of screening by flexible sigmoidoscopy compared with screening by faecal occult blood testing. BMJ (1998) 1.58

Low-cost, office-based, screening colonoscopy. Am J Gastroenterol (1994) 1.55

Recommendations on screening for colorectal cancer in primary care. CMAJ (2016) 1.52

Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS Med (2012) 1.38

Colonoscopy screening markedly reduces the occurrence of colon carcinomas and carcinoma-related death: a closed cohort study. Gastrointest Endosc (2012) 1.24

A retrospective observational study examining the characteristics and outcomes of tumours diagnosed within and without of the English NHS Bowel Cancer Screening Programme. Br J Cancer (2012) 1.21

Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening. Br J Surg (1997) 1.21

Prevalence and malignant potential of colorectal polyps in asymptomatic, average-risk men. Am J Gastroenterol (1991) 1.21

The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial. J Med Screen (2005) 1.20

A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. Int J Cancer (2011) 1.19

Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database Syst Rev (2013) 1.17

Endoscopic and surgical complications of work-up in screening for colorectal cancer. Dis Colon Rectum (1996) 1.16

Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut (2012) 1.14

Screening colonoscopy in Chinese and Western patients: a comparative study. Am J Gastroenterol (2005) 1.12

Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study. Br J Cancer (2008) 1.12

Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. World J Gastroenterol (2006) 1.09

Volume and yield of screening colonoscopy at a tertiary medical center after change in medicare reimbursement. Am J Gastroenterol (2003) 1.05

Prevalence and risk of colorectal adenoma in asymptomatic Koreans aged 40-49 years undergoing screening colonoscopy. J Gastroenterol Hepatol (2010) 1.05

Colorectal screening is associated with reduced colorectal cancer risk: a case-control study within the population-based Ontario Familial Colorectal Cancer Registry. Cancer Causes Control (2005) 1.03

Screening colonoscopy in asymptomatic average-risk Koreans: analysis in relation to age and sex. J Gastroenterol Hepatol (2007) 1.03

Polypectomy of adenomas in the prevention of colorectal cancer: 10 years' follow-up of the Telemark Polyp Study I. A prospective, controlled population study. Scand J Gastroenterol (1996) 1.02

Uptake and positive predictive value of fecal occult blood tests: A randomized controlled trial. Prev Med (2013) 0.97

The usefulness of colonoscopy as a screening test for detecting colorectal polyps. Hepatogastroenterology (2007) 0.90

Early detection of colorectal cancer with faecal occult blood test screening. Br J Surg (2010) 0.90

Screening and primary prevention of colorectal cancer: a review of sex-specific and site-specific differences. J Med Screen (2013) 0.88

A prospective study of the frequency and the topographical distribution of colon neoplasia in asymptomatic average-risk Chinese adults as determined by colonoscopic screening. Gastrointest Endosc (2005) 0.88

Is the type of test used for mass colorectal cancer screening a determinant of compliance? A cluster-randomized controlled trial comparing fecal occult blood testing with flexible sigmoidoscopy. Cancer Detect Prev (2006) 0.86

Capsule colonoscopy increases uptake of colorectal cancer screening. BMC Gastroenterol (2012) 0.84

Screening for colorectal neoplasia with faecal occult blood testing compared with flexible sigmoidoscopy directly in a 55-56 years' old population. Int J Colorectal Dis (1997) 0.81

The Canadian Association of Gastroenterology position on colon cancer screening. Can J Gastroenterol (2003) 0.81

Gene expression analysis using a highly sensitive DNA microarray for colorectal cancer screening. Anticancer Res (2014) 0.78

Tackling colorectal cancer as a public health issue: what can the gastroenterologist do? Can J Gastroenterol (2012) 0.76